Assessing the efficacy of targeted therapy using circulating epithelial tumor...
150903 maintrac-hormonal-therapy
1. Maintrac®
A tool for monitoring therapy success in solid tumors:
circulating epithelial tumor cells
Transfusion Medicine Center Bayreuth TZB, Germany
3. Circulating Tumor Cells
from solid tumors
S Carcinomas are from
epithelial origin
S Carcinomas dissiminate
epithelial cells
⇒ CETCs
(circulating epithelial
tumor cells)
Y.
Shiozawa,
A
M
Havens,
K
J
Pienta
and
R
S
Taichman,
Leukemia
(2008)
22,
941–950
14. Effect of therapy switch
Therapy switch
to aromatase
inhibitors
may lead to lower
tumor cell levels.
15. maintenance
therapy
maintrac
cell counting
every 3 month
Increase
in cell numbers
take
change of therapy
into consideration
maintrac
cell counting
every 3 month
Decrease
in cell numbers
go on with therapy
maintrac
cell counting
every 3 month
Recommendation:
If cell numbers
increase,
change of therapy
may be considered
monitor every
3 months
21. CETC and tumor size
Maybe more
agressivity than
tumor size?
22. CETC and nodal status
Nodal status
was not this
meaningful
23. after end
of therapy
maintrac
cell counting
after 3 month
Increase
in cell numbers
restart
maintenance herapy
Decreasing
or stable
cell numbers
maintrac
cell counting
after 3 month
Decreasing
or stable
cell numbers
maintrac
cell counting
every 6 month
Recommendation:
If cell numbers
increase,
take restart of therapy
in consideration and
and monitor...
24. Association Transfusion Medicine Center in Bayreuth - TZB
SIMFO Specialized Immunology Research + Development GmbH
& Laboratory Dr. Ulrich Pachmann
SIMFO GmbH
Kurpromenade 2
95448 Bayreuth
Germany
www.maintrac.com